Unknown

Dataset Information

0

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection.

ABSTRACT: Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.

SUBMITTER: Baldeon Vaca G 

PROVIDER: S-EPMC10516494 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)-lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intran  ...[more]

Similar Datasets

Unknown Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease.
| S-EPMC8492382 | biostudies-literature
Unknown Intranasal administration of convalescent plasma protects against SARS-CoV-2 infection in hamsters.
| S-EPMC10171892 | biostudies-literature
Unknown Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease.
| S-EPMC9208357 | biostudies-literature
Unknown Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2.
| S-EPMC9240059 | biostudies-literature
Unknown Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection.
| S-EPMC9731714 | biostudies-literature
Unknown A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
| S-EPMC8324831 | biostudies-literature
Unknown Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern.
| S-EPMC8818312 | biostudies-literature
Unknown Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants.
| S-EPMC10250859 | biostudies-literature
Unknown Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection.
| S-EPMC9671113 | biostudies-literature
Unknown SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies.
| S-EPMC10290737 | biostudies-literature